glp-1 receptor agonist after roux-en-y gastric bypass Weight Reduction with Agonists and Paths for Discontinuation While Maintaining Weight Loss Obesity Treatment With Bariatric Surgery

GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2030

no major safety concerns were observed

The glp-1 agonists market is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026 to 2032.

For people who stopped taking GLP-1 weight-loss medications, patients regained about 60% of the weight []

Youve likely heard about glucagon-like peptide-1 agonists commonly referred to as GLP-1 medications, and more widely recognized through pharmaceutical brand names like Ozempic and Mounjaro.

After a few years of injectable dominance, oral formulations are emerging as a game-changer for adherence and ease of use thanks to their lack of cold-chain requirement, but also a game-changer for their ability to unlock the long-term maintenance opportunity [14]